ICDM 2024

Clinical diabetes and therapeutics 1 How to modify disease: timing and modality Chair(s): Jeong-Taek Woo, Sang Ah Chang
Thursday 10 October, 08:40~10:10
Room 1

The session will cover key strategies for changing the fate of diabetes through pharmacological, behavioral, or surgical interventions, emphasizing precise timing and effective therapies. It will start with new-onset type 1 diabetes, highlighting how early immune interventions can affect disease progression and outcomes. Then, it will compare lifestyle changes with or without medications to stop or delay type 2 diabetes. Finally, the session will look at the complicated link between diabetes and obesity, and examine optimal timing for surgical interventions.

S2-1 Kevan HeroldYale University, USA: Immune and beta cell therapies to change the course of type 1 diabetes

S2-2 Soo Jin YunKyung Hee University, Korea: Prediabetes: lifestyle intervention alone or in combination with medication

S2-3 Chih-Kun HuangChina Medical University Hospital, Taiwan: Diabetes with obesity: best timing to consider surgery

Panel discussion

S2-Panel 1
Gyuri KimSungkyunkwan University, Korea
S2-Panel 2
Tae Jung OhSeoul National University, Korea
S2-Panel 3
Se Hee MinUniversity of Ulsan, Korea

Clinical diabetes and therapeutics 2 Dark side of GLP-1 based therapy Chair(s): Byung Joon Kim, Suk Chon
Thursday 10 October, 13:40~15:10
Room 1

GLP-1 based therapies have revolutionized diabetes management, but concerns about potential adverse effects persist. This session explores the association between GLP-1 receptor agonists and suicidality, psychological disorders, bowel obstruction, and pancreatic-biliary disorders. Experts will delve into the mechanisms, risk factors, and patient characteristics that may contribute to these adverse events. The session aims to provide insights into mitigating these risks while optimizing the benefits of incretin-based therapies.

S6-1 Mi Kyung KimKeimyung University, Korea: Can GLP-1 RAs cause an increase in suicidality: psychological disorders?

S6-2 Chang Hee JungUniversity of Ulsan, Korea: Can incretin-based drugs increase bowel obstruction?

S6-3 Seung Min ChungYeungnam University, Korea: Can incretin-based drugs increase pancreatic-biliary disorders: why/how?

Clinical diabetes and therapeutics 3 The expanding role of SGLT2 inhibitors beyond cardiorenal protection Chair(s): Moon-Kyu Lee, Sung Rae Kim
Thursday 10 October, 17:00~18:30
Room 2

SGLT2 inhibitors have proven effective for type 2 diabetes, heart failure, and chronic kidney disease. This session explores their emerging additional benefits beyond these traditional areas. We will discuss the role of SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD), comparing them to other antidiabetic agents, examine their potential anti-cancer effects, and consider the possibility of SGLT2 inhibitors as anti-aging agents. The session aims to provide a comprehensive understanding of these new effects and their mechanisms, extending beyond the well-established benefits of SGLT2 inhibitors, offering insights into their broader therapeutic potential.

S10-1 Jun Sung MoonYeungnam University, Korea: Update on the effect of SGLT2 inhibitors against MASLD; comparison with other anti-diabetic agents

S10-2 Yun Kyung ChoUniversity of Ulsan, Korea: SGLT2 inhibitors as emerging anticancer agents

S10-3 Daisuke YabeKyoto University, Japan: Incretins, energy metabolism and beyond

Panel discussion

S10-Panel 1
Ji Yoon KimSungkyunkwan University, Korea
S10-Panel 2
Kyuho KimThe Catholic University of Korea, Korea
S10-Panel 3
Han Na JungHallym University, Korea

Clinical diabetes and therapeutics 4 Oral GLP-1 based therapy: beginning of a new era Chair(s): Kun-Ho Yoon, Mikyung Kim
Friday 11 October, 14:20~15:50
Room 1

Oral GLP-1 based therapy will open the beginning of a new era in treating diabetes and metabolic diseases. Three cutting-edge lectures are prepared for alternative routes of GLP-1 receptor agonist delivery, oral semaglutide, and oral nonpeptide GLP-1 receptor agonists. This session will help you better understand the oral GLP-1 based therapy and navigate through the latest trends and future implications.

S15-1 Young Min ChoSeoul National University, Korea: Alternative routes of GLP-1 receptor agonist delivery

S15-2 Jang Won SonThe Catholic University of Korea, Korea: Oral semaglutide: similarity and difference from subcutaneous semaglutide

S15-3 Eun RohHallym University, Korea: Oral non-peptide GLP-1 receptor agonists

Panel discussion

S15-Panel 1
Sangmo HongHanyang University, Korea
S15-Panel 2
Kyung-Soo KimCHA University, Korea
S15-Panel 3
Mi Hae SeoSoonchunhyang University, Korea

구분		사전등록 (~2024년 9월 2일까지)		현장등록 (2024년 10월 9일 ~ 11일)
구분		KDA회원	비회원	KDA회원	비회원
9~11일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩280,000	₩350,000	₩370,000	₩450,000
9~11일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩180,000	₩230,000	₩250,000	₩270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩170,000	₩210,000	-
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩110,000	₩140,000	-
저녁 식사	전체	₩55,000

Program details

평점안내 (For Korean)